Wealth Enhancement Advisory Services LLC Invests $35,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Wealth Enhancement Advisory Services LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 12,421 shares of the company’s stock, valued at approximately $35,000.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Xeris Biopharma by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock valued at $16,810,000 after buying an additional 519,897 shares during the last quarter. Alpine Global Management LLC raised its position in Xeris Biopharma by 11.1% in the 1st quarter. Alpine Global Management LLC now owns 300,000 shares of the company’s stock valued at $663,000 after buying an additional 30,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Xeris Biopharma by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock valued at $278,000 after buying an additional 10,632 shares during the last quarter. NEA Management Company LLC purchased a new stake in Xeris Biopharma in the 1st quarter valued at $926,000. Finally, Bayesian Capital Management LP purchased a new stake in Xeris Biopharma in the 1st quarter valued at $37,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Stock Performance

XERS stock opened at $3.15 on Thursday. The company has a market capitalization of $469.60 million, a price-to-earnings ratio of -7.00 and a beta of 2.70. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.46 and a fifty-two week high of $3.64. The stock has a fifty day moving average of $2.99 and a 200-day moving average of $2.53.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on XERS. Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Monday. HC Wainwright raised their target price on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.